Gilead Sciences, INC. 8-K Filing
Ticker: GILD · Form: 8-K · Filed: Nov 19, 2025 · CIK: 882095
Sentiment: neutral
Filing Stats: 420 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2025-11-19 08:30:34
Key Financial Figures
- $0.001 — h registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Se
Filing Documents
- tm2531634d1_8k.htm (8-K) — 23KB
- 0001104659-25-113968.txt ( ) — 182KB
- gild-20251115.xsd (EX-101.SCH) — 3KB
- gild-20251115_lab.xml (EX-101.LAB) — 33KB
- gild-20251115_pre.xml (EX-101.PRE) — 22KB
- tm2531634d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of Directors;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 19 , 2025, Gilead Sciences, Inc., a Delaware corporation (the "Company"), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025. Ms. Telman's employment with the Company will terminate later in the month.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer Date: November 19, 2025